UPDATE: More bad news for those that have this disease with no treatment
Sarepta's Shares Drop After FDA Casts Doubts on Proposed Drug
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.
With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.